Circulating hsa-miR-5096 predicts 18F-FDG PET/CT positivity and modulates somatostatin receptor 2 expression: a novel miR-based assay for pancreatic neuroendocrine tumors

Gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs) are rare diseases encompassing pancreatic (PanNETs) and ileal NETs (SINETs), characterized by heterogeneous somatostatin receptors (SSTRs) expression. Treatments for inoperable GEP-NETs are limited, and SSTR-targeted Peptide Receptor Radionuc...

Full description

Saved in:
Bibliographic Details
Published in:Frontiers in oncology 2023-05, Vol.13, p.1136331-1136331
Main Authors: Bocchini, Martine, Tazzari, Marcella, Ravaioli, Sara, Piccinini, Filippo, Foca, Flavia, Tebaldi, Michela, Nicolini, Fabio, Grassi, Ilaria, Severi, Stefano, Calogero, Raffaele Adolfo, Arigoni, Maddalena, Schrader, Joerg, Mazza, Massimiliano, Paganelli, Giovanni
Format: Article
Language:English
Subjects:
functional imaging (positron-emission tomography)
miRNA – microRNA
Oncology
pancreatic neuroendocrine tumors
PRRT (peptide receptor radionuclide therapy)
SSTR2
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Gastro-entero-pancreatic neuroendocrine tumors (GEP-NETs) are rare diseases encompassing pancreatic (PanNETs) and ileal NETs (SINETs), characterized by heterogeneous somatostatin receptors (SSTRs) expression. Treatments for inoperable GEP-NETs are limited, and SSTR-targeted Peptide Receptor Radionuclide Therapy (PRRT) achieves variable responses. Prognostic biomarkers for the management of GEP-NET patients are required. 18 F-FDG uptake is a prognostic indicator of aggressiveness in GEP-NETs. This study aims to identify circulating and measurable prognostic miRNAs associated with 18 F-FDG-PET/CT status, higher risk and lower response to PRRT.
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2023.1136331